Skip to main content
. 2020 Jan 23;10:3106. doi: 10.3389/fmicb.2019.03106

FIGURE 3.

FIGURE 3

ASP-105 Biocide Inhibits the growth of CA-MRSA in wounds: (A) Images of mice infected with 104 CA- MRSA treated with either ASP-105, Bacitracin, or vehicle through +3 days (N = 5 for each group). Neither bacitracin nor ASP-105-treated animals show any bioluminescence. (B) Radiance plots (mean ±SEM) of mouse wound bed over 7 days infected with CA-MRSA ASP-105-treated animals show significantly lower burdens through treatment. (C) Wound area measurement (mean ±SEM) when treated with either ASP-105 or vehicle initiating after surgical dressing removal, ASP-105 treatment had no significant impact on wound closure. (D) Gross wound categorical scoring (mean ±SEM). (E) No significant difference observed in daily mean group weights. Statistical difference by Student’s T-test (∗p < 0.05).